Papadakis J A, Mikhailidis D P, Winder A F
Department of Chemical Pathology and Human Metabolism, Royal Free Hospital and School of Medicine, University of London, UK.
Cardiovasc Res. 1998 Nov;40(2):265-71. doi: 10.1016/s0008-6363(98)00222-3.
The epidemiological studies linking lipid variables and stroke are reviewed. These studies indicate that serum total cholesterol (TC) levels are associated positively with thrombotic and negatively with haemorrhagic strokes. Relationships for other lipid fractions are not as clearly defined. The results of trials with lipid lowering drugs suggest that only statins effectively reduce the incidence of stroke. Differences between trial results may be due to variation in the extent of reduction of TC levels. Possible underlying mechanisms for benefit and the apparent superiority of statins are also discussed. The reduction in the risk of thrombotic stroke with statins is most evident through meta-analyses (p < 0.001) and less impressive in individual trials (p < 0.03). This difference is largely attributable to the small number of events in trials primarily aimed at evaluating ischaemic heart disease (IHD) reduction. This also means that benefit may be limited to those with established IHD. IHD and thrombotic stroke share common risk factors and patients with one condition are at high risk of developing the other. Therefore, one additional reason for using statins in these patients is that these drugs can effectively prevent IHD-related events including deaths.
本文综述了脂质变量与中风之间的流行病学研究。这些研究表明,血清总胆固醇(TC)水平与血栓性中风呈正相关,与出血性中风呈负相关。其他脂质组分的关系则没有那么明确。降脂药物试验的结果表明,只有他汀类药物能有效降低中风的发生率。试验结果的差异可能是由于TC水平降低程度的不同。文中还讨论了获益的潜在机制以及他汀类药物明显的优势。通过荟萃分析(p<0.001)可以明显看出,他汀类药物降低血栓性中风风险的效果最为显著,而在个别试验中(p<0.03)则不那么明显。这种差异很大程度上归因于主要旨在评估缺血性心脏病(IHD)减少情况的试验中事件数量较少。这也意味着获益可能仅限于患有确诊IHD的患者。IHD和血栓性中风有共同的危险因素,患有其中一种疾病的患者发生另一种疾病的风险很高。因此,在这些患者中使用他汀类药物的另一个原因是,这些药物可以有效预防包括死亡在内的与IHD相关的事件。